Get in
touch

Feedback plc

Information for investors, shareholders and analysts about Feedback plc

Feedback plc (AIM: FDBK) provides innovative software and systems through our trading subsidiary, Feedback Medical.

Feedback Medical is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.

Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.

Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

Five reasons to invest in Feedback plc

 

  1. Aligned to key areas of NHS strategic priority, strong NHS contacts & large total addressable market (TAM).
  2. Strong position on intellectual property – Bleepa is the only clinical communication platform UKCA marked for medical image display.
  3. Strong network of partners – well-positioned to capitalise on opportunities in the UK and abroad with a combined potential TAM of ‘£10bn’.
  4. Breadth of growth opportunities extends internationally across several markets, built on a highly scalable software-as-a-service model.
  5. Led by a team that brings together expertise from medical and specialist IT healthcare backgrounds.

Our latest investor presentation

Play video

Our latest investor update for the twelve months ended May 31, 2025.

~£314m annual TAM estimated in UK

Company estimated total addressable market in the UK – annual
1 2 3 4
NHS trusts NHS – CDCs / ICSs NHS community pharmacies Private hospitals (UK) TOTAL
TAM £28m £81m £191m £14m £314m

 

Alignment with UK Government priorities

 

Reforming Elective Care Plan Darzi report 10 Year Health Plan for England
Priority Alignment
Straight-to-test pathways expansion Bleepa enables clinically informed straight-to-test pathways (DEAG)
CDC expansion DEAG pathway uses CDCs to improve pathway efficiency
92% 18-week RTT target priority Bleepa leads to a 63% reduction in RTT time compared to national target
Hospital to community shift With straight-to-test pathways and CDCs, Bleepa prevents up to 90% of unnecessary outpatient appointments
Independent sector relationship Well placed to work with NHS providers to implement Bleepa
Priority Alignment
Neighbourhood health services Bleepa ensures care in community setting where possible (90% outpatient appt reduction)
Drive productivity in hospitals Bleepa shows number of decisions within standard time slot can increase by up to 6x
Tilt towards technology Feedback Medical is at forefront of technology to improve NHS care delivery
Tackling inequality Bleepa removes barriers to care ie geographical and wealth inequality, and reduces carbon emissions with asynchronous working and shift to community
Priority Alignment
Analogue to digital Bleepa enables digital-first, asynchronous approach to patient pathways
Hospital to community Bleepa is effective at delivering A&G (DEAG) services across providers to divert patients from hospitals
Sickness to prevention By improving productivity and diverting patients from secondary care, frees up funding for prevention
Neighbourhood health services Well placed to deliver on digital aspects of NH – patient management, collaboration and data sharing across care settings

Regulatory support

Data governance Medical device regulation Clinical risk
  • National £2.3bn programme for multiple CDCs to drive faster diagnosis for patients
  • Growing need to connect CDCs to other care settings and streamline patient pathways > reduce wait times
  • Drive to meet the faster diagnosis standard – 75% of urgent referrals diagnosed or cancer ruled out within 28 days
  • Growing need to clearly identify cancer diagnosis standard breaches and improve patient care
  • DCB 0129 – clinical risk and safety standard, risk analysis and mitigation for product design, manufacturing and operational processes
  • ISO 13485 certification demonstrating consistent quality of product releases

Explore more

Regulatory news (RNS)

Financial reports & presentations

Share information

AIM rule 26